WO1999030706A1 - Compositions antilipemiques combinant un inhibiteur de lipoproteine (a) et une statine - Google Patents

Compositions antilipemiques combinant un inhibiteur de lipoproteine (a) et une statine Download PDF

Info

Publication number
WO1999030706A1
WO1999030706A1 PCT/US1998/023480 US9823480W WO9930706A1 WO 1999030706 A1 WO1999030706 A1 WO 1999030706A1 US 9823480 W US9823480 W US 9823480W WO 9930706 A1 WO9930706 A1 WO 9930706A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
statin
pharmaceutical composition
kit
acceptable salt
Prior art date
Application number
PCT/US1998/023480
Other languages
English (en)
Inventor
Charles Larry Bisgaier
Roger Schofield Newton
Randy Ranjee Ramharack
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP98956562A priority Critical patent/EP1037623A1/fr
Priority to HU0100349A priority patent/HUP0100349A3/hu
Priority to KR1020007006370A priority patent/KR20010033017A/ko
Priority to PL98343851A priority patent/PL343851A1/xx
Priority to CA002299397A priority patent/CA2299397A1/fr
Priority to IL13436498A priority patent/IL134364A0/xx
Priority to NZ502874A priority patent/NZ502874A/en
Priority to AU13060/99A priority patent/AU1306099A/en
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Priority to BR9813539-2A priority patent/BR9813539A/pt
Priority to JP2000538689A priority patent/JP2003524582A/ja
Publication of WO1999030706A1 publication Critical patent/WO1999030706A1/fr
Priority to IS5385A priority patent/IS5385A/is
Priority to NO20002965A priority patent/NO20002965D0/no
Priority to AU2003244047A priority patent/AU2003244047A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition pharmaceutique renfermant un inhibiteur de lipoprotéine (a) et une statine, qui a un effet inhibiteur sur la HMG-CoA réductase. Ce type de composition est utile pour le traitement des maladies vasculaires.
PCT/US1998/023480 1997-12-12 1998-11-04 Compositions antilipemiques combinant un inhibiteur de lipoproteine (a) et une statine WO1999030706A1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
NZ502874A NZ502874A (en) 1997-12-12 1998-11-04 Antihyperlipidemic statin-lp(a) inhibitor combinations
KR1020007006370A KR20010033017A (ko) 1997-12-12 1998-11-04 과지질혈증 치료제인 스타틴-ＬＰ(ａ) 억제제의 병용 제제
PL98343851A PL343851A1 (en) 1997-12-12 1998-11-04 Antihyperlipidemic statin-lp(a) inhibitor combinations
CA002299397A CA2299397A1 (fr) 1997-12-12 1998-11-04 Compositions antilipemiques combinant un inhibiteur de lipoproteine (a) et une statine
IL13436498A IL134364A0 (en) 1997-12-12 1998-11-04 ANTIHYPERLIPIDEMIC STATIN-LP (a) INHIBITOR COMBINATIONS
EP98956562A EP1037623A1 (fr) 1997-12-12 1998-11-04 Compositions antilipemiques combinant un inhibiteur de lipoproteine (a) et une statine
AU13060/99A AU1306099A (en) 1997-12-12 1998-11-04 Antihyperlipidemic statin-lp(a) inhibitor combinations
HU0100349A HUP0100349A3 (en) 1997-12-12 1998-11-04 Pharmaceutical compositions containing antihyperlipidemic statin-lp(a) inhibitor
BR9813539-2A BR9813539A (pt) 1997-12-12 1998-11-04 Combinações de inibidor de lp(a) e estatina anti-hiperlipidêmicas
JP2000538689A JP2003524582A (ja) 1997-12-12 1998-11-04 抗高脂血症性スタチン−Ｌｐ（ａ）阻害剤配合物
IS5385A IS5385A (is) 1997-12-12 2000-02-25 Statin-LP(A)-tálma-lyfjablöndur við fitudreyra
NO20002965A NO20002965D0 (no) 1997-12-12 2000-06-09 Antihyperlipidemisk statin-LP(a) inhibitor kombinasjoner
AU2003244047A AU2003244047A1 (en) 1997-12-12 2003-08-29 Antihyperlipidemic stain-Lp(a) inhibitor combinations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6943297P 1997-12-12 1997-12-12
US60/069,432 1997-12-12

Publications (1)

Publication Number Publication Date
WO1999030706A1 true WO1999030706A1 (fr) 1999-06-24

Family

ID=22088939

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/023480 WO1999030706A1 (fr) 1997-12-12 1998-11-04 Compositions antilipemiques combinant un inhibiteur de lipoproteine (a) et une statine

Country Status (14)

Country Link
EP (1) EP1037623A1 (fr)
JP (1) JP2003524582A (fr)
KR (1) KR20010033017A (fr)
AU (2) AU1306099A (fr)
BR (1) BR9813539A (fr)
CA (1) CA2299397A1 (fr)
HU (1) HUP0100349A3 (fr)
IL (1) IL134364A0 (fr)
IS (1) IS5385A (fr)
NO (1) NO20002965D0 (fr)
NZ (1) NZ502874A (fr)
PL (1) PL343851A1 (fr)
WO (1) WO1999030706A1 (fr)
ZA (1) ZA9811349B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001051078A1 (fr) * 2000-01-10 2001-07-19 Amylin Pharmaceuticals, Inc. Utilisation d'exendines et d'agonistes de ces dernieres pour moduler les taux de triglycerides et pour traiter la dyslipidemie
EP1275388A1 (fr) * 2000-02-10 2003-01-15 Takeda Chemical Industries, Ltd. Inhibiteurs de tnf-alpha
EP1586644A2 (fr) * 1999-08-09 2005-10-19 Universite Catholique De Louvain Medicament pour la prévention et/ou la traitement des cardiopathies ischémiques, des acrosyndromes, et le développement des tumeurs, et dans la cicatrisations des plaies
US7138375B2 (en) 1997-01-07 2006-11-21 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for lowering plasma lipid

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013801A1 (fr) * 1992-01-17 1993-07-22 The Procter & Gamble Company Traitement de l'arteriosclerose
WO1993016690A1 (fr) * 1992-02-25 1993-09-02 Warner-Lambert Company Compositions cytoprotectrices contenant du pyruvate et des antioxydants
EP0738510A2 (fr) * 1995-04-20 1996-10-23 L'oreal Utilisation d'un inhibiteur d'hmg coenzyme A reductase pour lutter contre le vieillissement de la peau
WO1997014403A1 (fr) * 1995-10-18 1997-04-24 Mary Kay Inc. Traitements de rupture de barriere pour peaux presentant une structure deterioree

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2016467A1 (fr) * 1989-06-05 1990-12-05 Martin Eisman Methode de traitement de l'atherosclerose des vaisseaux peripheriques a l'aide d'un inhibiteur de l'hmg coa reductase et (ou) d'un inhibiteur de la squalene synthetase
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
AU732465B2 (en) * 1996-04-17 2001-04-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013801A1 (fr) * 1992-01-17 1993-07-22 The Procter & Gamble Company Traitement de l'arteriosclerose
WO1993016690A1 (fr) * 1992-02-25 1993-09-02 Warner-Lambert Company Compositions cytoprotectrices contenant du pyruvate et des antioxydants
EP0738510A2 (fr) * 1995-04-20 1996-10-23 L'oreal Utilisation d'un inhibiteur d'hmg coenzyme A reductase pour lutter contre le vieillissement de la peau
WO1997014403A1 (fr) * 1995-10-18 1997-04-24 Mary Kay Inc. Traitements de rupture de barriere pour peaux presentant une structure deterioree

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DIMITROULAKOS ET AL: "HMG-CoA Reductase Mediates the Biological Effects of Retinoc Acid on Human Neuroblastoma Cells: Lovastatin Specifically Targets P-Glycoprotein-Expressing Cells", NATURE MEDICINE, vol. 2, no. 3, March 1996 (1996-03-01), pages 326 - 333, XP002103070 *
GLUECK ET AL: "Gemfibrozil-Lovastatin Therapy for Primary Hyperlipoproteinemia", THE AMERICAN JOURNAL OF CARDIOLOGY, vol. 70, no. 1, 1 July 1992 (1992-07-01), pages 1 - 9, XP002103067 *
HAAG ET AL: "Lovastatin Inhibits Receptor-Stimulated Ca++-Influx in Retinoic Acid Differentiated U937 and HL-60 Cells", CELLULAR SIGNALLING, vol. 6, no. 7, 1994, pages 835 - 742, XP002103068 *
KRAUSE ET AL: "Emerging Therapies in Atherosclerosis", EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 4/5, 1995, pages 353 - 387, XP002103072 *
RAMHARACK ET AL: "Retinoids Inhibit Primary Cynomolgus Monkey Hepatocyte Lipoprotein(a) Levels", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 238, no. 1, 8 September 1997 (1997-09-08), pages 48 - 52, XP002103071 *
RAMIRES ET AL: "Effect of Gemfibrozil versus Lovastatin on Increased Serum Lipoprotein(a) Levels of Patients with Hypercholesterolemia", INTERNATIONAL JOURNAL OF CARDIOLOGY, vol. 48, no. 2, 1995, pages 115 - 120, XP002103069 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138375B2 (en) 1997-01-07 2006-11-21 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for lowering plasma lipid
EP1586644A2 (fr) * 1999-08-09 2005-10-19 Universite Catholique De Louvain Medicament pour la prévention et/ou la traitement des cardiopathies ischémiques, des acrosyndromes, et le développement des tumeurs, et dans la cicatrisations des plaies
EP1586644A3 (fr) * 1999-08-09 2008-06-25 Universite Catholique De Louvain Medicament pour la prévention et/ou la traitement des cardiopathies ischémiques, des acrosyndromes, et le développement des tumeurs, et dans la cicatrisations des plaies
WO2001051078A1 (fr) * 2000-01-10 2001-07-19 Amylin Pharmaceuticals, Inc. Utilisation d'exendines et d'agonistes de ces dernieres pour moduler les taux de triglycerides et pour traiter la dyslipidemie
JP2003519667A (ja) * 2000-01-10 2003-06-24 アミリン・ファーマシューティカルズ，インコーポレイテッド トリグリセリドレベルの調節および脂質異常血症の治療のためのエキセンジンおよびそのアゴニストの使用
EP1275388A1 (fr) * 2000-02-10 2003-01-15 Takeda Chemical Industries, Ltd. Inhibiteurs de tnf-alpha
EP1275388A4 (fr) * 2000-02-10 2003-11-26 Takeda Chemical Industries Ltd Inhibiteurs de tnf-alpha

Also Published As

Publication number Publication date
HUP0100349A2 (hu) 2001-07-30
NZ502874A (en) 2004-03-26
JP2003524582A (ja) 2003-08-19
NO20002965L (no) 2000-06-09
PL343851A1 (en) 2001-09-10
KR20010033017A (ko) 2001-04-25
HUP0100349A3 (en) 2002-02-28
BR9813539A (pt) 2000-10-10
AU2003244047A1 (en) 2003-09-25
IS5385A (is) 2000-02-25
EP1037623A1 (fr) 2000-09-27
CA2299397A1 (fr) 1999-06-24
AU1306099A (en) 1999-07-05
NO20002965D0 (no) 2000-06-09
ZA9811349B (en) 1999-06-14
IL134364A0 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
AP1207A (en) Combination therapy.
AU8554898A (en) Therapeutic combinations comprising amlodipin and atorvastatin
EP1045691B1 (fr) Combinaisons de statine-carboxyalkylether
US20070149578A1 (en) Combination Therapy
US20140012042A1 (en) Calcium Dicarboxylate Ethers
WO1999030706A1 (fr) Compositions antilipemiques combinant un inhibiteur de lipoproteine (a) et une statine
US20020103252A1 (en) Statin-carboxyalkylether combinations
EP1280522B1 (fr) Combinaison de carboxyalkylethers avec des agents antihypertenseurs et leur utilisation
US20040092574A1 (en) Statin-Lp(a) inhibitor combinations
EP1481962A1 (fr) Nouveau carboxyéthylether reduisant la cholesterolémie
MXPA00002105A (en) Antihyperlipidemic statin-lp(a) inhibitor combinations
US20030225123A1 (en) Antihypertensive agents and use
MXPA00002104A (en) Carton with panel locking means
MXPA00002085A (en) Combination therapy comprising amlodipine and a statin compound

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 134364

Country of ref document: IL

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE HR HU ID IL IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2299397

Country of ref document: CA

Ref country code: CA

Ref document number: 2299397

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09485242

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 13060/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 502874

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/002105

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1998956562

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 538689

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1020007006370

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1998956562

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020007006370

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1020007006370

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1998956562

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998956562

Country of ref document: EP